Amylyx Pharmaceuticals, Inc.
NASDAQ:AMLXBiotechnology
Healthcare
$26.20 +0.93%
+$0.14 today
- Market cap
- $3.37B
- Beta
- -0.16
- P/E (TTM)
- -11.3
- EPS (TTM)
- -$1.36
52W Low $4.80High $18.61
Volume 1.76M
Average 1.21M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$153.29M
FY 2025 · Annual
Net Income
-$144.74M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 22.23M | 380.79M | 87.37M | 0 |
| Cost of Revenue | 0 | 2.99M | 25.44M | 42.16M | 525K |
| Gross Profit | 0 | 19.24M | 355.35M | 45.22M | (525K) |
| Gross Margin | — | 86.5% | 93.3% | 51.8% | — |
| Research & Development | 44.04M | 93.45M | 128.19M | 104.08M | 90.4M |
| Selling, General & Admin | 38.93M | 127.13M | 188.36M | 114.33M | 62.89M |
| Operating Expenses | 82.69M | 220.58M | 316.54M | 359.95M | 152.77M |
| Depreciation & Amortization | 52K | 487K | 1.09M | 904K | 525K |
| EBITDA | (87.88M) | (197.11M) | 55.39M | (290.98M) | (144.16M) |
| EBITDA Margin | — | -886.7% | 14.5% | -333.0% | — |
| Operating Income | (82.69M) | (201.34M) | 38.8M | (314.73M) | (153.29M) |
| Operating Margin | — | -905.7% | 10.2% | -360.2% | — |
| Interest Income | 36K | 4.29M | 16.16M | 13.81M | 9.3M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (5.24M) | 3.74M | 15.5M | 12.6M | 8.6M |
| Income Before Tax | (87.93M) | (197.6M) | 54.3M | (302.14M) | (144.69M) |
| Pre-Tax Margin | — | -888.9% | 14.3% | -345.8% | — |
| Income Tax Expense | 0 | 774K | 5.03M | (393K) | 46K |
| Net Income | (87.93M) | (198.38M) | 49.27M | (301.74M) | (144.74M) |
| Net Margin | — | -892.4% | 12.9% | -345.4% | — |
| EPS (Basic) | (1.52) | (2.98) | 0.73 | (4.43) | (1.53) |
| EPS (Diluted) | (1.52) | (2.98) | 0.70 | (4.43) | (1.53) |
| 57.86M | 66.51M | 67.23M | 68.14M | 94.57M | |
| 57.86M | 66.51M | 69.99M | 68.14M | 94.57M |
AMLX Earnings Waterfall · TTM
NASDAQ:AMLX · Revenue to Net Income
Key Ratios
EPS$-1.42
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-12.7
P/S Ratio0.0
Analysis
$0 of revenue converted into -$163.2M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-1.42, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Nov 12, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 12, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 12, 2026 | |
| 10-Q | Quarterly report | Nov 5, 2026 | |
| 8-K | Current report | Nov 5, 2026 |
How much revenue does AMLX generate?
Amylyx Pharmaceuticals, Inc. (AMLX) reported $0.00 of revenue in fiscal 2025.
Is AMLX profitable?
Amylyx Pharmaceuticals, Inc. (AMLX) reported -$144.74M of net income.
Continue the stock analysis
Jump to another research area for this company.